Literature DB >> 6255389

Observations on the synthesis of carcinoembryonic antigen by an established human colonic carcinoma cell line.

B Drewinko, L Y Yang.   

Abstract

Some properties and kinetics of synthesis of the carcinoembryonic antigen (CEA-LoVo) produced by an established human colon carcinoma cell line were analyzed. CEA-LoVo was assayed by the method of Chu and Reynoso which was standardized against the activity of the First British Standard for CEA. CEA-LoVo was stable at -20 and 4 degrees C. At 37 degrees C, CEA-LoVo degraded at the rate of 1.4%/day in cell-free supernatants, and at the rate of 6.6%/day in the supernatants of monolayer cultures. CEA-LoVo was sensitive to enzymatic treatment with trypsin (approximately 55% loss)) and extraction of PCA (> 70% loss). The elution profile of CEA-LoVo in Concanavalin A-Sepharose B coincided with that of the First British Standard for CEA. No A or B blood group antigenic activity was noted. Studies employing immunofluorescent and horseradish peroxidase-labeled antibody techniques demonstrated heavy membrane and moderate intracytoplasmic localization. The greatest amount of net synthesis occurred for cells in the stationary phase while CEA-LoVo release occurred maximally in the lag phase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255389     DOI: 10.1159/000225466

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  5 in total

1.  Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells.

Authors:  L V Levin; T W Griffin; L R Childs; S Davis; D E Haagensen
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Metastatic breast cancer with constantly low CEA blood levels. A subgroup with unfavorable prognosis?

Authors:  G Krieger; H E Wander; M Kneba; M Prangen; G Bandlow; G A Nagel
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

3.  Selection and characterisation of Affimers specific for CEA recognition.

Authors:  Shazana Hilda Shamsuddin; David G Jayne; Darren C Tomlinson; Michael J McPherson; Paul A Millner
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

4.  The clinical value of immunohistochemically demonstrable CEA in breast cancer: a possible method of selecting patients for adjuvant chemotherapy.

Authors:  S R Smith; A Howell; A Minawa; J M Morrison
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

5.  Tumour lysis as a factor affecting blood levels of CEA.

Authors:  J B Quayle
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.